
|Articles|July 12, 2012
The Pharma Top 20s
Advertisement
Top 20 Global Therapeutic Classes: The surge in antidiabetics clearly reflects the consequences of lifestyle changes that are edging around the world.
Top 25 Corporations by US Sales: Pfizer holds on at home despite falling Lipitor sales, but the loss of the Lipitor patent at the end of 2011 will make this lead increasingly tenuous.
Top 25 Corporations by US Prescriptions: Increased prescribing of generics saw Watson, Amneal and Lupin Laboratories surge ahead in 2011.
Major patent expiries in 2012.
Advertisement
Related to this article

Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.

DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.

As specialty drug complexity grows, agentic technology puts the right access, adherence, and affordability resources at the provider’s fingertips at prescribing.

J&J’s separations of Kenvue and DePuy Synthes test whether Innovative Medicine and MedTech create more value together than apart.

Dr. Joe Geraci of NetraMark explains how AI analysis of clinical trial data can uncover hidden responder subgroups, separate true drug responders from placebo responders, and potentially rescue drug assets that appeared to fail in Phase II.

Parexel’s Stacy Hurt explains why AI can speed up clinical research but can’t replace the lived experience of patients.

The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.
Advertisement
Advertisement
Trending on PharmExec
1
Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo
2
Keeping Human Expertise at the Center of AI
3
Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout
4
Johnson & Johnson's Strategic Shift: Why Diversification Is Giving Way to Focus
5

